Tay-Sachs Disease Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Tay-Sachs is a lysosomal storage disorder caused by the deficiency of vital enzymes called beta-hexosaminidase A (Hex-A). The role of Hex-A is to degrade a fatty substance or lipid called GM-2 ganglioside. In the absence of the Hex-A enzymes, GM-2 accumulates abnormally in cells, especially in the nerve cells or neurons, of the brain. In children, the destructive process begins in the fetus early in pregnancy. However, a baby with Tay-Sachs disease appears normal till six months of age when its develops slowly. By about two years of age, most children experience recurrent seizures and diminishing mental functioning. The infant gradually regresses, and is eventually unable to crawl, turn over, sit or reach out. There is no specific treatment for Tay-Sachs disease.

The drug candidates in Tay-Sachs therapeutics pipeline include, but not limited to, CCP-010. Some of the major companies having drugs in the Tay-Sachs therapeutics pipeline includes Lysogene, and Castle Creek Pharmaceuticals.

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.